Impact of COVID-19: How has the pandemic affected how we do science?

Adrian J. Carter’s career at Boehringer Ingelheim spans almost 35 years including 8 years as head of neuropharmacology. Adrian subsequently spent 10 years in business development where he led the negotiations for several large licensing collaborations, co-commercialization deals, and patent agreements. Since 2011, he has been vice president and global head of Discovery Research Coordination where he is responsible for guiding research policy, leading strategic research initiatives, and steering operational themes. He is also a member of the Discovery Research Leadership Committee. Adrian represents Boehringer Ingelheim on the board of trustees for the Structural Genomics Consortium (SGC) and the Scientific and Medical Institute (NMI), as well as being vice chairperson of the Research and Innovation Strategies (RIS) Group of EFPIA and a member of the strategic advisory board of the Biotech Cluster Rhein-Neckar (BioRN).

Dr. Julie Maxton CBE is the Executive Director of the Royal Society, the first woman in 350 years to hold the post. Before taking up her position at the Royal Society Julie was Registrar at the University of Oxford, the first woman in 550 years in the role. She is an Honorary Fellow of University College Oxford, a Bencher of the Middle Temple, a Freeman of the Goldsmith’s Company, and a Board member of Engineering UK, the Charities Aid Foundation, Haberdasher Aske’s School and of the International Advisory Board of the Blavatnik School of Governance at Oxford University. Originally trained as a barrister at the Middle Temple, Julie combined a career as a practising lawyer with that of an academic.

Prof. Dr. Veronika von Messling is Directorate-General of the Life Science Division at the German Federal Ministry of Education and Research. She obtained her veterinary degree and her doctorate degree in veterinary virology from the Veterinary School Hannover, Germany. After postdoctoral training at Mayo Clinic in Rochester, MN, she was Assistant Professor at INRS-Institut Armand-Frappier in Laval, QC, and then Associate Professor at Duke-NUS Medical School, Singapore, before becoming Director of the Veterinary Division at Paul-Ehrlich-Institute, the German Federal Institute of Vaccines and Biomedicines, in Langen, Germany. Her expertise lies in the development of novel prophylactic and therapeutic strategies against infectious diseases.

Kyle Myers is an assistant professor of business administration in the Technology and Operations Management unit at the Harvard Business School. His research revolves around the economics of innovation and lies at the intersection of science, business, and public policy. He has received funding from the Kauffman Foundation, the Sloan Foundation, and the National Bureau of Economic Research. Professor Myers holds a Ph.D. from the Wharton School’s Department of Health Care Management and Economics. He has a M.S. in Health Policy and Management and a B.S. in Biology from Penn State University. Prior to joining the Harvard Business School, he was a post-doctoral fellow at the National Bureau of Economic Research and worked at the Centers for Disease Control and Prevention

Daniel Hook is CEO of Digital Science. He has been involved in research information management for over a decade and has been helped to position Digital Science as a key infrastructure provider across research over the last few years. He is a regular co-author of Digital Science’s analysis reports. Daniel is a mathematical physicist by training, and is affiliated with Imperial College London, Washington University in St Louis and the University of Cambridge. He is a Fellow of the Institute of Physics and serves on the ORCID board.